Last reviewed · How we verify
Hemostatic Agent
A hemostatic agent promotes blood clotting and stops bleeding by enhancing coagulation cascade activation or platelet function.
A hemostatic agent promotes blood clotting and stops bleeding by enhancing coagulation cascade activation or platelet function. Used for Perioperative bleeding control, Hemorrhage management in cancer surgery.
At a glance
| Generic name | Hemostatic Agent |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Hemostatic agent / Coagulation enhancer |
| Modality | Small molecule |
| Therapeutic area | Hematology / Surgery / Oncology |
| Phase | Phase 3 |
Mechanism of action
Hemostatic agents work through various mechanisms to control hemorrhage, including activation of coagulation factors, enhancement of platelet aggregation, or promotion of fibrin formation. These agents are used to manage bleeding in surgical, traumatic, or pathological contexts. The specific mechanism depends on the formulation—whether it acts systemically on coagulation factors or locally at the bleeding site.
Approved indications
- Perioperative bleeding control
- Hemorrhage management in cancer surgery
Common side effects
- Thrombosis
- Allergic reaction
- Fever
Key clinical trials
- Clinical Study of Patients Treated With PuraBond Haemostatic Agent During Abdominal Aorta Open Repair
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection (NA)
- Clinical Comparison of Alb-PRF vs PRF on Postoperative Morbidity Following FGG Harvesting (NA)
- IMAGES: Identifying Metabolic Imaging Association With Genicular Artery Embolization Success (NA)
- Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion (NA)
- Biodentine Pulpotomy vs Metapex Pulpectomy in Primary Molars: Clinical & Radiographic Comparison of Outcomes in Irreversible Pulpitis Cases (NA)
- Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemostatic Agent CI brief — competitive landscape report
- Hemostatic Agent updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI